Rituximab: historia, farmacología y perspectivas

the rituximab tartrate is part of the first generation of anti-cd20 monoclonal antibodies used as biological therapy in stock 3 chronic lymphoproliferative syndromes, in autoimmune diseases, and in others entities where is present a b lymphocyte proliferation. it is a murine/human chimera monoclonal antibody obtained by genetic engineering, with a proven safety and effectiveness and that may be used as monotherapy or combined with chemotherapy. in present review are showed the historical backgrounds, the pharmacology and the perspectives of this drug.